Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06250829 | Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer(Pre-PLaN) | unknown | — | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT01871454 | Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers | unknown | Phase 2 | 59 | University of LouisvilleOTHER |
| 1 |
| Feb 7, 2024 |
| clinicaltrials |
| NCT05526573 | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | unknown | — | 148 | Azienda Sanitaria-Universitaria Integrata di UdineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05573373 | Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05647590 | SBRT/RT in Oligometastatic Stage IV NSCLC | unknown | N/A | 10 | University Hospital OstravaOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06232265 | An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore | unknown | — | 108 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06207292 | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer(STARTNEWERA-OM) | unknown | N/A | 100 | Radiotherapy Oncology Centre "Santa Maria" HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05296278 | Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC | unknown | Phase 2 | 70 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05984017 | A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma | unknown | — | 130 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05248022 | Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| NCT06195683 | Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.(NSCLC) | unknown | Phase 2 | 23 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04789252 | Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer(TUM-DC) | unknown | — | 64 | University of Milano BicoccaOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04937972 | SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma(FLYFLY) | unknown | Phase 2 | 71 | Hunan Province Tumor HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05611879 | Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | unknown | Phase 2 | 30 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT02098954 | Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers | unknown | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03646968 | Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study(SAVE) | unknown | Phase 2 | 43 | Yongchang ZhangOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03646994 | Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer | unknown | — | 40 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03647111 | Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer | unknown | — | 120 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03647592 | Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer | unknown | — | 30 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04071418 | I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy(RISIRLC) | unknown | — | 30 | Peking University Third HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04322591 | Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial(POSEIDON) | unknown | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04397432 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Retrospective Study(SELECT-1) | unknown | — | 878 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05991206 | A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC | unknown | — | 200 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182800 | Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy | unknown | Phase 2 | 35 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT03256981 | Stereotactic Body Radiotherapy for the Treatment of OPD(HALT) | unknown | Phase 2 / Phase 3 | 113 | Institute of Cancer Research, United KingdomOTHER | 5 | Dec 26, 2023 | clinicaltrials |
| NCT06180239 | Segmentectomy vs Lobectomy | unknown | — | 800 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT02950337 | Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer | unknown | N/A | 41 | Loyola UniversityOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06163846 | Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence. | unknown | — | 415 | IRCCS San RaffaeleOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06174857 | Efficacy of Osimertinib in Patients With Lung Cancer | unknown | — | 100 | Hunan Province Tumor HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05542485 | PLAsma Genomic Testing in Patients With Advanced Non-Small Cell Lung Cancer: The PLAN Study(PLAN) | unknown | — | 97 | Royal College of Surgeons, IrelandOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT05730972 | TEAS for the Treatment of Pain in Bone Metastases of Lung Cancer | unknown | N/A | 188 | The Third Affiliated hospital of Zhejiang Chinese Medical UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06165874 | [68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04636775 | Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) | unknown | — | 46 | Jun Zhang, MD, PhDOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT02871856 | International Lung Screen Trial (ILST)(ILST) | unknown | N/A | 2,000 | The University of QueenslandOTHER | 2 | Dec 5, 2023 | clinicaltrials |
| NCT04632758 | Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 3 | 292 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05329025 | A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05669105 | Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research | unknown | — | 200 | Sanguine BiosciencesINDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06143735 | A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors | unknown | Phase 2 | 99 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05291403 | Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion | unknown | N/A | 141 | Qianfoshan HospitalOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05812534 | Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases(CBC) | unknown | Phase 2 | 36 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06140082 | Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression | unknown | — | 477 | LI YANOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05311709 | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities(SOLUCOM) | unknown | Phase 2 | 100 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05673590 | Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 612 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT04467801 | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy(Ipat-Lung) | unknown | Phase 2 | 60 | Jun Zhang, MD, PhDOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05863325 | A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06110663 | A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy | unknown | Phase 3 | 314 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 9, 2024source: clinicaltrials